<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03704623</url>
  </required_header>
  <id_info>
    <org_study_id>Parecoxib vs Paracetamol</org_study_id>
    <nct_id>NCT03704623</nct_id>
  </id_info>
  <brief_title>Parecoxib vs Paracetamol in the Treatment of Acute Renal Colic</brief_title>
  <official_title>Parecoxib vs Paracetamol in the Treatment of Acute Renal Colic Due to Ureteric Calculi: Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amiri Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted to compare the efficacy and safety of Parecoxib versus&#xD;
      Paracetamol for treatment of acute renal colic due to ureteric stones.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients will be randomized to one of the two treatment groups. Group 1 patients&#xD;
      will receive IV 1 g of Paracetamol while group 2 patients will receive 40 mg of Parecoxib IV.&#xD;
&#xD;
      The Visual Analogue Scale (VAS) will be calculated on presentation and at 30 minutes after&#xD;
      analgesia administration. Patients who do not respond to an initial dose of the analgesia&#xD;
      will receive rescue analgesia in the form of Morphine, 01.mg/kg, IV.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Actual">August 15, 2020</completion_date>
  <primary_completion_date type="Actual">August 15, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Eligible patients will be randomized to one of the two treatment groups.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>The emergency department (ED) nurse will do randomization by drawing one of the sealed closed envelopes that contain the analgesic to be administered.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The need for rescue analgesia (Morphine)</measure>
    <time_frame>30 minutes</time_frame>
    <description>Patient who had persistent pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of adverse effects due to medication used</measure>
    <time_frame>24 hours</time_frame>
    <description>Assessment of adverse effects of the drug used</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Acute Renal Colic</condition>
  <condition>Ureteric Stone</condition>
  <arm_group>
    <arm_group_label>Paracetamol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive IV 1 g of Paracetamol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Parecoxib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 40 mg of Parecoxib IV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol</intervention_name>
    <description>Paracetamol 1g IV</description>
    <arm_group_label>Paracetamol</arm_group_label>
    <other_name>Perfalgan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Parecoxib</intervention_name>
    <description>Parecoxib 40 mg IV</description>
    <arm_group_label>Parecoxib</arm_group_label>
    <other_name>Dynastat</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical signs and symptoms consistent with acute renal colic&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitivity to either Paracetamol or Parecoxib.&#xD;
&#xD;
          -  History of peptic ulcer.&#xD;
&#xD;
          -  Pregnant or breastfeeding females.&#xD;
&#xD;
          -  Patients with hepatic impairment (Child-Pugh score &gt;10).&#xD;
&#xD;
          -  Patients with chronic kidney disease (CKD) Stage 4 or 5 (eGFR &lt;30mls/min).&#xD;
&#xD;
          -  History of coronary ischemia, peripheral vascular or cerebrovascular disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abdullatif AL-Terki, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Amiri Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Al-Amiri Hospital</name>
      <address>
        <city>Kuwait</city>
        <country>Kuwait</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kuwait</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>October 10, 2018</study_first_submitted>
  <study_first_submitted_qc>October 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2018</study_first_posted>
  <last_update_submitted>August 26, 2020</last_update_submitted>
  <last_update_submitted_qc>August 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>Ahmed R. EL-Nahas</investigator_full_name>
    <investigator_title>Professor of Urology</investigator_title>
  </responsible_party>
  <keyword>Acute renal colic</keyword>
  <keyword>Ureteric stone</keyword>
  <keyword>Selective COX2 inhibitor</keyword>
  <keyword>Parecoxib</keyword>
  <keyword>Paracetamol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ureteral Calculi</mesh_term>
    <mesh_term>Ureterolithiasis</mesh_term>
    <mesh_term>Colic</mesh_term>
    <mesh_term>Renal Colic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Parecoxib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

